There's been a very significant investment through the Canadian immunity task force. Through that task force and its funding mechanisms, a whole host of studies and surveys are being done across Canada in the general population. That includes blood donors, persons with HIV, seniors in long-term care, health care workers and kids. We will have some very good data on the level of antibodies and immunity in the population.
Prior to the vaccine, because we did manage to suppress a lot of transmission in Canada, the level of immunity from the natural infection was low. It would be less than 10% for the most part, and a few percentage points when we started the beginning of the second wave, for example.
However, with vaccines and with the uptake in vaccines, it means that a very significant proportion of the population will now benefit and have immunity. The funding, the studies and the surveys will continue over time to monitor the immunity afforded by the vaccine, or the immunity afforded by the virus.